ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Cyclerion Therapeutics, Inc. ?
1
Poor long term growth as Net Sales has grown by an annual rate of -14.10% and Operating profit at 14.39% over the last 5 years
2
The company has declared Positive results for the last 8 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD -2.83 MM
- NET PROFIT(HY) Higher at USD -3.07 MM
- ROCE(HY) Highest at -22.43%
3
Risky - Negative EBITDA
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 1.38%, its profits have risen by 67%
4
High Institutional Holdings at 41.35%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
5
Underperformed the market in the last 1 year
- The stock has generated a return of 1.38% in the last 1 year, much lower than market (S&P 500) returns of 12.33%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Cyclerion Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Cyclerion Therapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Cyclerion Therapeutics, Inc.
5.59%
-0.38
91.51%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-14.10%
EBIT Growth (5y)
14.39%
EBIT to Interest (avg)
-35.38
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.41
Sales to Capital Employed (avg)
0.16
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
41.35%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.16
EV to EBIT
-1.89
EV to EBITDA
-1.89
EV to Capital Employed
1.28
EV to Sales
3.16
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-67.44%
ROE (Latest)
-37.67%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend17What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -2.83 MM
NET PROFIT(HY)
Higher at USD -3.07 MM
ROCE(HY)
Highest at -22.43%
RAW MATERIAL COST(Y)
Fallen by 0% (YoY
NET SALES(9M)
Higher at USD 1.98 MM
DEBTORS TURNOVER RATIO(HY)
Highest at 8.28 times
-12What is not working for the Company
DEBT-EQUITY RATIO
(HY)
Highest at -35.08 %
CASH AND EQV(HY)
Lowest at USD 6.64 MM
OPERATING PROFIT(Q)
Lowest at USD -1.67 MM
PRE-TAX PROFIT(Q)
Lowest at USD -1.64 MM
NET PROFIT(Q)
Lowest at USD -1.64 MM
Here's what is working for Cyclerion Therapeutics, Inc.
Net Sales
At USD 1.98 MM has Grown at inf%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (USD MM)
Operating Cash Flow
Highest at USD -2.83 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Debtors Turnover Ratio
Highest at 8.28 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Net Sales
Higher at USD 1.98 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months
Net Sales (USD MM)
Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Cyclerion Therapeutics, Inc.
Pre-Tax Profit
At USD -1.64 MM has Fallen at -98.49%
over average net sales of the previous four periods of USD -0.83 MMMOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (USD MM)
Net Profit
At USD -1.64 MM has Fallen at -98.49%
over average net sales of the previous four periods of USD -0.83 MMMOJO Watch
Near term Net Profit trend is very negative
Net Profit (USD MM)
Debt-Equity Ratio
Highest at -35.08 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Operating Profit
Lowest at USD -1.67 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is negative
Operating Profit (USD MM)
Pre-Tax Profit
Lowest at USD -1.64 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (USD MM)
Net Profit
Lowest at USD -1.64 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is negative
Net Profit (USD MM)
Cash and Eqv
Lowest at USD 6.64 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
